Your session is about to expire
← Back to Search
Monoclonal Antibodies
SGN-MesoC2 for Solid Tumors
Phase 1
Recruiting
Research Sponsored by Seagen Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
Participants must have histologically- or cytologically-confirmed metastatic or locally advanced unresectable ovarian cancer, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma, colorectal cancer (CRC), mesothelioma, or other solid tumors, have relapsed or progressed following standard therapies, or for which no standard therapy is available.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 1 year 4 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is looking at a new drug called SGN-MesoC2 for treating advanced solid tumors, which are cancers that have grown in one place or spread to other parts of the body. Patients
Who is the study for?
This trial is for adults weighing at least 40 kg with certain advanced solid tumors, including ovarian cancer, NSCLC, pancreatic adenocarcinoma, colorectal cancer, and mesothelioma. Participants must have tried standard treatments without success or have no available standard options. They should be relatively active (ECOG score of 0 or 1) and have at least one measurable tumor lesion.
What is being tested?
SGN-MesoC2 is being tested in this study. It's an experimental antibody-drug conjugate designed to target and kill cancer cells while sparing normal ones. The trial has three parts: determining the right dose (Parts A & B) and assessing safety and effectiveness (Part C).
What are the potential side effects?
Potential side effects of SGN-MesoC2 may include damage to healthy cells leading to various symptoms depending on which organs are affected; however, specific side effects aren't listed here.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am fully active or can carry out light work.
Select...
My cancer is advanced, cannot be surgically removed, and has not responded to standard treatments.
Select...
I can provide a sample of my tumor, either from previous tests or by a new biopsy if safe.
Select...
I weigh at least 40 kg.
Select...
My ovarian cancer is resistant to platinum-based treatments and has returned or worsened after standard treatment.
Select...
My pancreatic cancer is advanced, cannot be surgically removed, or has returned.
Select...
My cancer has worsened after standard treatments, and I've had specific chemotherapy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 1 year 4 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 1 year 4 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants with adverse events (AEs)
Number of participants with dose modifications
Number of participants with dose-limiting toxicities (DLTs)
Secondary study objectives
Best response
Disease control rate (DCR)
Duration of response (DOR)
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: PF-08052666Experimental Treatment1 Intervention
PF-08052666 monotherapy
Find a Location
Who is running the clinical trial?
Seagen Inc.Lead Sponsor
210 Previous Clinical Trials
73,973 Total Patients Enrolled
Medical MonitorStudy DirectorSeagen Inc.
1,678 Previous Clinical Trials
989,733 Total Patients Enrolled